Related Experiment Video

Updated: Jul 24, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.7K

MiR-590-5p promotes cisplatin resistance via targeting hMSH2 in ovarian cancer

Bing Li1, Xuejie Xu1, Linlin Zheng1

  • 1Department of Medical Oncology, the Affiliated Hospital of Putian University, Putian, 351100, Fujian province, China.

Molecular Biology Reports
|July 1, 2023
PubMed
Abstract

Insights

MicroRNA-590-5p promotes cisplatin resistance in ovarian cancer by downregulating hMSH2. Inhibiting microRNA-590-5p can decrease cancer cell viability, suggesting therapeutic potential for hMSH2 and microRNA-590-5p in treating resistant ovarian cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer chemotherapy resistance mechanisms remain unclear.
  • MicroRNAs play crucial roles in cancer development and drug resistance.

Purpose of the Study:

  • To investigate the role of microRNA-590-5p (miR-590-5p) in regulating hMSH2 expression.
  • To explore the impact of miR-590-5p and hMSH2 on cisplatin resistance in ovarian cancer.

Main Methods:

  • Bioinformatic prediction identified miR-590-5p as an hMSH2 regulator.
  • Ovarian cancer cell lines (sensitive SKOV3, resistant SKOV3-DDP) were used for functional and molecular assays.
  • Dual luciferase reporter assay confirmed the direct targeting of hMSH2 by miR-590-5p.

Main Results:

  • miR-590-5p was upregulated, and hMSH2 was downregulated in cisplatin-resistant cells.
  • hMSH2 upregulation weakened cell viability under cisplatin treatment.
  • miR-590-5p mimics enhanced cell viability, while inhibition decreased it, confirming its role in cisplatin resistance.

Conclusions:

  • miR-590-5p promotes cisplatin resistance in ovarian cancer by negatively regulating hMSH2.
  • Inhibition of miR-590-5p reduces ovarian cancer cell viability in the presence of cisplatin.
  • miR-590-5p and hMSH2 represent potential therapeutic targets for cisplatin-resistant ovarian cancer.
Keywords:
Cisplatin resistanceOvarian cancerhMSH2miR-590-5p

More Related Videos

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

13.5K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.2K